Amit is a Managing Director in Deloitte Consulting’s Life Sciences practice. Amit has more than 25 years of management consulting experience and has led multiple projects in both strategy and operations Amit co-leads the Next Generation Therapies practice. The practice focuses on advising clients on taking advantage of and/or developing strategic responses to new disruptive technologies in cell and gene therapies space. Amit has worked with Life Science clients in the U.S. Europe and Asia on high-impact projects.
Amit also has experience as Vice President at Leerink Swann & Co., a boutique investment bank focused on the life sciences. He helped innovative life science companies raise capital, identify merger and acquisition targets and negotiate strategic partnerships and alliances. He helped his clients generate nearly $1 billion of market value through the deals he helped broker.
Amit publishes extensively in the business press and in peer reviewed academic journals on personalized medicine. Amit has presented at multiple conferences in North America, South America and Europe and worked with industry associations on value-based care and risk sharing contracts in light of new technology paradigms.
Amit holds an MBA in finance and technological innovation from the MIT Sloan School of Management and a bachelor’s degree in history and premed from Occidental College. Prior to business school, Amit conducted research in neurobiology at the California Institute ofTechnology and was an American diplomat posted in China and the Middle East.

I am a core member of Deloitte’s NextGen Practice, with a focus on helping cell and gene companies set up their supply chain and commercial platform to launch their products globally. I co-lead Deloitte’s Industry Working Group (IWG), working closely with industry leaders to design patient-centric solutions that provide CGT access to a broader patient population.
Relevant experiences:
1. Developed a digital strategy to support the first gene-editing product launch in the US and EMEA
2. Performed the market landscape assessment for cell and gene therapies and developed the investment strategy for a PE firm
3. Led patient journey development and market sizing for an ultra-rare disease gene therapy, and develop launch strategy in Saudi, Russia, Japan, and Brazil
Supported commercial site certification across 80+ hospitals within the US for a CAR-T product
4. Drove the global launch readiness for the most expensive gene therapy product outside of the US, with a projected $1B sales revenue in 2020

I’m a Partner based in Shanghai, China with a focus on biotech and next generation therapies practice. We often take a China specific view and help clients to understand the intricate and fast-evolving policies environment and what it means for entry strategy, regulatory path, market access, and go-to-market models. We also tackle next-generation specific issues such as site certification and supply chain visibility. My experience in CGT:
1. Led multiple projects with leading overseas biopharma companies to help define China product regulatory paths, market access and GTMs including CAR-T, targeted oncology drugs, and rare disease drugs
2. Worked on global supply chain and China commercial excellence to define China entry and supply chain models for Cell & Gene Therapies
3. Worked on the launch of multiple CAR-T products access and pricing strategy in China
4. Worked on the companion genetic diagnosis tests clinical development and GTM assessment as part of the CGT product portfolio
5. Represent the Deloitte Next Generation Therapies practice in China with thought leadership on driving In China For China business models

John is a Shanghai based Manager at the Strategy & Business Design service
line, also known as Monitor Deloitte and now part of Strategy, Analytics and M&A offering portfolio, of Deloitte Consulting. He studied Biomedical Sciences at University of Oxford where he specialized in scientific data analysis as well as experimental testing; through which he developed a research oriented and data driven approach to solving problems.
John possesses a diverse skill set from strategy to operations in Life Sciences
and Health Care consulting. His strong written and verbal communication skills also contributed to his successful track record in interacting with clients across levels. John is fluent in English, Mandarin Chinese and Cantonese Chinese.
Selected project experience:
• Assessed China competitive landscape as well as pricing and reimbursement environment for a leading British multinational pharmaco’s hepatocellular carcinoma CAR T; designed likely market access journey for client’s CAR T by formulating various reimbursement scenarios and price volume relationship
• Evaluated China go to market model options for a leading Japanese multinational pharmco’s portfolio of gene therapies having identified relevant regulatory barriers; designed entry roadmap from entity set up, clinical trials, product and materials import to commercialization
• Estimated China market size and attractiveness for a leading Japanese multinational medical device company’s cell processing center; identified use cases and customer segments and developed unique value propositions
John holds a Master and a Bachelor degree in Biomedical Sciences from University of Oxford.